PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsDrug from genetically altered goats rejected

BioNews

Drug from genetically altered goats rejected

Published 9 June 2009 posted in News and appears in BioNews 347

Author

BioNews

PET BioNews

European regulators have rejected a licence application for a new drug based on a human protein extracted from the milk of genetically altered goats. If the drug had been given the go-ahead by the European Medicines Agency (EMEA), it would have been the first treatment of its kind to be...

European regulators have rejected a licence application for a new drug based on a human protein extracted from the milk of genetically altered goats. If the drug had been given the go-ahead by the European Medicines Agency (EMEA), it would have been the first treatment of its kind to be approved for clinical use. Atryn was developed by US firm GTC Biotherapeutics, for treating patients affected by a rare inherited blood clotting disorder. The company has said it will appeal against the decision, and also plans to apply to the Food and Drug Administration (FDA) for permission to sell the drug in the US next year.


Atryn contains the human version of antithrombin (AT), a blood protein that blocks the formation of clots. People born with congenital antithrombin deficiency have low levels of the protein, which can lead to an increased risk of abnormal blood clots forming - particularly in 'high-risk' situations, such as when patients are undergoing surgery. Infusions of Atryn would temporarily control the disorder, say its manufacturers, who had tested the drug on 14 patients. However, because of changes to the way it was administered after the trial had begun, the EMEA would only consider results from five of the participants - too few, it said, to determine whether Atryn was safe or not.


The protein is made by inserting the human AT gene into goat embryos, creating genetically altered animals that act as living drug factories. To ensure the drug is produced in the correct place, the AT gene is hooked up with the 'control switch' for casein, a protein exclusively present in milk. Several biotech companies are hoping to use this approach to produce large quantities of human proteins for treating a range of diseases. Another 'pharming' technique being used by some firms is to breed hens that produce human proteins in their eggs.


Therapeutic AT protein is currently obtained by purifying it from human blood. GTC has 57 goats that produce AT in their milk - potentially a much cheaper and efficient way of producing the drug, according to company director Geoffrey Cox. 'It takes just 18 months to produce a lactating animal and in a single year one goat produces the equivalent of 90,000 blood collections', he told the BBC News website. Another advantage of the approach is that it bypasses contamination concerns with products derived from human blood plasma products.


The EMEA acknowledges that the small number of patients treated so far is down to the fact that the disease only affects one person in 3-5000, but says it needs results from at least 12 people. It also says that the company didn't carry out enough studies to see if Atryn would trigger an immune response, a potential risk with any protein-based drug. The firm is now planning to test Atryn on a further 17 people for its US application. Despite the rejection in Europe, GTC's executives said they were encouraged that none of the EMEA's objections related to the way in which Atryn is produced. 'They identified concerns, and none of them relates to a goat', said spokesman Thomas Newberry.

Related Articles

PET BioNews
News
9 June 2009 • 2 minutes read

Go-ahead for drug from GM goats

by Dr Jess Buxton

A new drug based on a human protein extracted from the milk of genetically altered goats has been approved for use by European regulators. Atryn, given the go-ahead by the European Medicines Agency (EMEA) last week, is the first treatment of its kind to be approved...

PET BioNews
News
9 June 2009 • 1 minute read

Drugs produced in eggs from GM hens

by BioNews

US scientists have discovered how to make hens lay eggs that contain proteins for use as drugs for humans. Reporting in the April issue of the journal Nature Biotechnology, the scientists, from the company AviGenics, said they inserted a new gene into the DNA of American white leghorn chicken embryos...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
9 June 2009 • 1 minute read

Cancer drugs from hen's eggs?

by BioNews

Scientists at the Roslin Institute, home of Dolly the sheep, hope to use genetically altered cloned chickens in the production of new drugs. The planned project, a joint venture with US biotech firm Viragen, was unveiled at a press conference in Edinburgh last week. The announcement followed earlier media reports...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
9 June 2009 • 1 minute read

Gene targeting used in sheep clones

by BioNews

Scientists at PPL Therapeutics have used gene targeting to produce cloned sheep with a precise genetic alteration. The UK biotech firm, which is the commercial offshoot of the institute that cloned Dolly the sheep, published their results in last week's Nature. Gene targeting allows researchers to add, replace or remove...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Potential pesticide threat to male fertility

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

27 June 2022 • 2 minutes read

UK report reveals public attitudes to fertility, genomics and embryo research

27 June 2022 • 2 minutes read

Shortage of sperm donors despite men willing to donate

27 June 2022 • 2 minutes read

North East London CCG proposes offering three funded IVF cycles

27 June 2022 • 2 minutes read

Fibrosis drugs reverse ovarian ageing in mice

27 June 2022 • 2 minutes read

Gene implicated in motor neurone diseases discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856